Losoxantrone HCl | CAS#88303-61-1 | anticancer drug

MedKoo Cat#: 599251 | Name: Losoxantrone HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Losoxantrone HCl is an experimental anticancer drug.

Chemical Structure

Losoxantrone HCl

CAS#88303-61-1

Theoretical Analysis

MedKoo Cat#: 599251

Name: Losoxantrone HCl

CAS#: 88303-61-1

Chemical Formula: C22H29Cl2N5O4

Exact Mass:

Molecular Weight: 498.40

Elemental Analysis: C, 53.02; H, 5.87; Cl, 14.23; N, 14.05; O, 12.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Losoxantrone hydrochloride; Losoxantrone HCl; NSC 357885; NSC-357885; NSC357885; DUP 941; CI 941;

IUPAC/Chemical Name

7-hydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-((2-hydroxyethyl)amino)ethyl)amino)dibenzo[cd,g]indazol-6(2H)-one dihydrochloride

InChi Key

XDMHALQMTPSGEA-UHFFFAOYSA-N

InChi Code

InChI=1S/C22H27N5O4.2ClH/c28-12-9-23-6-7-25-15-4-5-16-20-19(15)22(31)18-14(2-1-3-17(18)30)21(20)26-27(16)11-8-24-10-13-29;;/h1-5,23-25,28-30H,6-13H2;2*1H

SMILES Code

O=C1C2=C3C(N(CCNCCO)N=C3C4=C1C(O)=CC=C4)=CC=C2NCCNCCO.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 498.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shea JA, Shamrock WF, Abboud CA, Woodeshick RW, Nguyen LQ, Rubino JT, Segretario J. Validation of cleaning procedures for highly potent drugs. I. Losoxantrone. Pharm Dev Technol. 1996 Apr;1(1):69-75. PubMed PMID: 9552333. 2: Goh BC, Vokes EE, Joshi A, Ratain MJ. Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours. Br J Cancer. 2002 Feb 12;86(4):534-9. PubMed PMID: 11870533; PubMed Central PMCID: PMC2375276. 3: Herman EH, Zhang J, Hasinoff BB, Tran KT, Chadwick DP, Clark JR Jr, Ferrans VJ. Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats. Toxicology. 1998 Jun 26;128(1):35-52. PubMed PMID: 9704904. 4: Huan SD, Natale RB, Stewart DJ, Sartiano GP, Stella PJ, Roberts JD, Symes AL, Finizio M. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2000 Apr;6(4):1333-6. PubMed PMID: 10778959. 5: Joshi AS, Pieniaszek HJ Jr, Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, Ratain MJ. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos. 2001 Feb;29(2):96-9. PubMed PMID: 11159796. 6: Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA, Eckhardt SG, Weiss GR, Rodriguez GI, Drengler R, Kraynak M, Hammond L, Finizio M, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clin Cancer Res. 1999 Feb;5(2):299-308. PubMed PMID: 10037178. 7: Liang H, Wu X, Guziec LJ, Guziec FS Jr, Larson KK, Lang J, Yalowich JC, Hasinoff BB. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35. PubMed PMID: 16859314. 8: Renner UD, Piperopoulos G, Gebhardt R, Ehninger G, Zeller KP. The oxidative biotransformation of losoxantrone (CI-941). Drug Metab Dispos. 2002 Apr;30(4):464-78. PubMed PMID: 11901102. 9: Hasinoff BB, Tran KT. The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane. J Inorg Biochem. 1999 Nov-Dec;77(3-4):257-9. PubMed PMID: 10643663. 10: Leteurtre F, Kohlhagen G, Paull KD, Pommier Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44. PubMed PMID: 8040892. 11: Richards LE, Sun JH. Identification of two regioisomeric monocarboxylic acid metabolites of losoxantrone (DuP 941; Biantrazole) excreted in human urine. Drug Metab Dispos. 1995 May;23(5):600-2. PubMed PMID: 7587938. 12: Kaufman PA. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol. 1999 Jun;26(3 Suppl 8):39-46. Review. PubMed PMID: 10403473. 13: Supino R, Polizzi D, Pavesi R, Pratesi G, Guano F, Capranico G, Palumbo M, Sissi C, Richter S, Beggiolin G, Menta E, Pezzoni G, Spinelli S, Torriani D, Carenini N, Dal Bo L, Facchinetti F, Tortoreto M, Zunino F. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology. 2001;61(3):234-42. PubMed PMID: 11574780. 14: Sissi C, Moro S, Richter S, Gatto B, Menta E, Spinelli S, Krapcho AP, Zunino F, Palumbo M. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Mol Pharmacol. 2001 Jan;59(1):96-103. PubMed PMID: 11125029. 15: Prasad KD, Trinath J, Biswas A, Sekar K, Balaji KN, Guru Row TN. Anthrapyrazolone analogues intercept inflammatory JNK signals to moderate endotoxin induced septic shock. Sci Rep. 2014 Nov 27;4:7214. doi: 10.1038/srep07214. PubMed PMID: 25428720; PubMed Central PMCID: PMC4245532. 16: Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB, Guziec FS Jr. Structure-activity studies with cytotoxic anthrapyrazoles. Oncol Rep. 2006 Jun;15(6):1575-80. PubMed PMID: 16685398. 17: Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6. PubMed PMID: 11717429; PubMed Central PMCID: PMC61101. 18: Loadman PM, Calabrese CR. Separation methods for anthraquinone related anti-cancer drugs. J Chromatogr B Biomed Sci Appl. 2001 Nov 25;764(1-2):193-206. Review. PubMed PMID: 11817028. 19: Abrams JS, Moore TD, Friedman M. New chemotherapeutic agents for breast cancer. Cancer. 1994 Aug 1;74(3 Suppl):1164-76. Review. PubMed PMID: 7913662. 20: Vandenberg TA. New developments in chemotherapy for metastatic breast cancer. Anticancer Drugs. 1994 Jun;5(3):251-9. Review. PubMed PMID: 7919449.